Brittany Meisenheimer
A5079769730- Neuroblastoma Research and Treatments
- Immune Cell Function and Interaction
- Immune cells in cancer
- CAR-T cell therapy research
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Ovarian cancer diagnosis and treatment
- interferon and immune responses
- Cancer Genomics and Diagnostics
- Occupational and environmental lung diseases
Dana-Farber Cancer Institute
2022-2023
Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment ex vivo. Using dynamic single-cell RNA sequencing explants treated with a agonist, observed CXCR3...
<div>Abstract<p>Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment <i>ex vivo</i>. Using dynamic single-cell RNA sequencing...
Abstract Background N of 1 treatment paradigms represent the pinnacle personalized medicine in which a patient’s tumors are profiled to guide treatment. Low-grade serous ovarian cancer (LGSC) is distinct subtype cancer, comprising ~10% carcinomas and typically characterized by younger age onset. Molecularly, these often alterations within Ras signaling pathway, including KRAS mutations. Clinically, LGSC resistant standard cytotoxic chemotherapy, but may have sensitivity hormonal therapy or...
<div>Abstract<p>Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment <i>ex vivo</i>. Using dynamic single-cell RNA sequencing...
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Abstract Background: Activation of the anti-viral STING pathway promotes antitumor immunity but agonists have yet to achieve clinical success. Understanding their mechanism action in human tumors is key developing STING-based therapies and combinations. Higher tumor expression correlates with better response treatment multiple cancers been shown silence downstream interferon avoid immune detection, demonstrating an important role for cell immunity. Recent mouse studies explored complex...